Myriad Genetics, Salt Lake City, announced that Myriad RBM, a wholly owned subsidiary of Myriad Genetics, has entered into a research collaboration with Sanofi, a global and diversified health care company, and Population Health Research Institute (PHRI) at Hamilton Health Sciences and McMaster University. Through this collaboration, Myriad RBM will perform protein biomarker research for the Outcome Reduction with Initial Glargine Intervention (ORIGIN) study. The relationship between the biomarker results and clinical outcomes will be analyzed by investigators at PHRI.
As part of the agreement, Myriad RBM will analyze over 8,000 serum samples collected in the ORIGIN study using its DiscoveryMAP 250+ quantitative immunoassay panel. Sanofi conceived of the application of Myriad RBM’s technology to ORIGIN with a goal of identifying biomarker profiles that may optimize treatment and improve patient care.
This collaboration could represent up to $10 million in companion diagnostic service revenue for Myriad over the next two fiscal years.
[source: Myriad Genetics]